Urge your members of Congress to support continued medical research funding
ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.
Congress has turned its attention to the FY 2017 budget process following the release of the Obama Administration’s proposed budget in February. Though the President’s proposal seeks $33.1 billion overall for NIH, a 2.5 percent increase over FY 2016, much of the sought increase would be in the form of mandatory funding earmarked for specific projects such as the National Cancer Moonshot being led by Vice President Biden, leaving the base budget for NIH at FY 2016 levels. And, although NIH received a substantial increase in funding for the current fiscal year, lawmakers need to recognize the value of biomedical research by maintaining the investment in the NIH.
Over 40 states have already passed cancer drug coverage parity legislation and ASH is now working with three additional state level coalitions to ensure that patients in these states also have equitable coverage for oral and IV anti-cancer treatments.
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with
the disease, both in the United States and globally.
Join the Grassroots Network to stay up to date on all of ASH’s Advocacy Campaigns.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology